DB
LYEL icon

Dmitry Balyasny’s Lyell Immunopharma LYEL Stock Holding History

Dmitry Balyasny’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,879
Closed -$1.65M – 3042
2024
Q3 		$1.65M Buy
59,879
+10,612
+22% +$312K ﹤0.01% 1751
2024
Q2 		$1.43M Buy
49,267
+37,429
+316% +$1.78M ﹤0.01% 1653
2024
Q1 		$528K Buy
+11,838
New +$507K ﹤0.01% 2026
2022
Q4 		– Sell
-1,675
Closed -$245K – 3034
2022
Q3 		$245K Buy
+1,675
New +$227K ﹤0.01% 2259
2022
Q2 		– Sell
-3,388
Closed -$342K – 2986
2022
Q1 		$342K Buy
+3,388
New +$410K ﹤0.01% 1897
2021
Q4 		– Sell
-6,427
Closed -$1.9M – 2461
2021
Q3 		$1.9M Buy
+6,427
New +$1.93M 0.01% 1158

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Dmitry Balyasny's LYEL Position: Q4 2024 in Review

Dmitry Balyasny sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 59,879 shares — an estimated $1.65M sold.

Dmitry Balyasny first reported a position in LYEL in Q3 2021 and held it in 6 quarters. The position peaked at $1.9M in Q3 2021. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Dmitry Balyasny reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 59,879 Lyell Immunopharma shares in Q4 2024, an estimated $1.65M.
  • Dmitry Balyasny first reported a position in Lyell Immunopharma in Q3 2021 and held it in 6 quarters.
  • Dmitry Balyasny's Lyell Immunopharma position peaked at $1.9M in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.